References: Treatment-resistant schizophrenia

  • Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017;74(7):675–84. https://www.ncbi.nlm.nih.gov/pubmed/28514486
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174(3):216–29. https://www.ncbi.nlm.nih.gov/pubmed/27919182
  • Hung GC, Liu HC, Yang SY, Pan CH, Liao YT, Chen CC, et al. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. J Clin Psychiatry 2016;77(1):60–6. https://www.ncbi.nlm.nih.gov/pubmed/26613551
  • Samara MT, Klupp E, Helfer B, Rothe PH, Schneider-Thoma J, Leucht S. Increasing antipsychotic dose for non response in schizophrenia. Cochrane Database Syst Rev 2018;5:CD011883. https://www.ncbi.nlm.nih.gov/pubmed/29750432
  • Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016;209(5):385–92. https://www.ncbi.nlm.nih.gov/pubmed/27388573
  • Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th Oxford: Wiley-Blackwell; 2018. https://www.wiley.com/en-au/The+Maudsley+Prescribing+Guidelines+in+Psychiatry,+13th+Edition-p-9781119442608
  • Tiihonen J, Taipale H, Mehtala J, Vattulainen P, Correll CU, Tanskanen A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 2019. https://www.ncbi.nlm.nih.gov/pubmed/30785608
  • Veerman SRT, Schulte PFJ, de Haan L. Treatment for negative symptoms in schizophrenia: A comprehensive review. Drugs 2017;77(13):1423–59. https://www.ncbi.nlm.nih.gov/pubmed/28776162